Abstract
Ligands selectively targeting β -amyloid in the living brain are promising candidates of therapeutics and early diagnosis tools for Alzheimers disease. Among the major stages of β -amyloid aggregation, monomers and oligomers are excellent targets to reduce neurotoxic brain damages for prevention of the disease progression, while oligomers and fibrils, abundant in the late stage of the disease, are pathological objectives to develop reliable imaging probes. So far, there have been many efforts to develop a wide variety of monovalent β -amyloid ligands such as thioflavin T, PIB, FDDNP, curcumin, and tramiprosate. However, pathology of Alzheimers disease is not fully understood yet so that there is currently no cure and further investigations on Alzheimers disease are needed. For past several years, multivalent β -amyloid ligands have offered an alternative route by enhancing binding affinity of drug candidates. In addition, it has been revealed that not only neurotoxicity due to the protein misfolding but also other factors are involved in the β -amyloid cascade such as oxidative stress, inflammation, metal chelation, and several types of neurotransmitters. Thus, there have been numerous studies to improve binding affinities of single β -amyloid ligands via adopting multivalent effects or to develop drug candidates targeting multiple stages of the pathological cascade. In this review, multivalent and multifunctional β - amyloid ligands and their promising aspects as an alternative approach to Alzheimers disease are discussed.
Keywords: β Amyloid, Aβ, multivalent, multifunction, ligand, Alzheimer's disease, AD drug, imaging probe, early diagnosis
Current Pharmaceutical Design
Title: Multivalent & Multifunctional Ligands to β-Amyloid
Volume: 15 Issue: 6
Author(s): YoungSoo Kim, Ji Hoon Lee, Jiyeon Ryu and Dong Jin Kim
Affiliation:
Keywords: β Amyloid, Aβ, multivalent, multifunction, ligand, Alzheimer's disease, AD drug, imaging probe, early diagnosis
Abstract: Ligands selectively targeting β -amyloid in the living brain are promising candidates of therapeutics and early diagnosis tools for Alzheimers disease. Among the major stages of β -amyloid aggregation, monomers and oligomers are excellent targets to reduce neurotoxic brain damages for prevention of the disease progression, while oligomers and fibrils, abundant in the late stage of the disease, are pathological objectives to develop reliable imaging probes. So far, there have been many efforts to develop a wide variety of monovalent β -amyloid ligands such as thioflavin T, PIB, FDDNP, curcumin, and tramiprosate. However, pathology of Alzheimers disease is not fully understood yet so that there is currently no cure and further investigations on Alzheimers disease are needed. For past several years, multivalent β -amyloid ligands have offered an alternative route by enhancing binding affinity of drug candidates. In addition, it has been revealed that not only neurotoxicity due to the protein misfolding but also other factors are involved in the β -amyloid cascade such as oxidative stress, inflammation, metal chelation, and several types of neurotransmitters. Thus, there have been numerous studies to improve binding affinities of single β -amyloid ligands via adopting multivalent effects or to develop drug candidates targeting multiple stages of the pathological cascade. In this review, multivalent and multifunctional β - amyloid ligands and their promising aspects as an alternative approach to Alzheimers disease are discussed.
Export Options
About this article
Cite this article as:
Kim YoungSoo, Lee Hoon Ji, Ryu Jiyeon and Kim Jin Dong, Multivalent & Multifunctional Ligands to β-Amyloid, Current Pharmaceutical Design 2009; 15 (6) . https://dx.doi.org/10.2174/138161209787315648
DOI https://dx.doi.org/10.2174/138161209787315648 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
"Tuberculosis Prevention, Diagnosis and Drug Discovery"
The Nobel Prize-winning discoveries of Mycobacterium tuberculosis and streptomycin have enabled an appropriate diagnosis and an effective treatment of tuberculosis (TB). Since then, many newer diagnosis methods and drugs have been saving millions of lives. Despite advances in the past, TB is still a leading cause of infectious disease mortality ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
Melanoma and Non-Melanoma Skin Cancer Treatment: Standard of Care and Recent Advances
In this thematic issue, we aim to provide a standard of care of the diagnosis and treatment of melanoma and non-melanoma skin cancer. The editor will invite authors from different countries who will write review articles of melanoma and non-melanoma skin cancers. The Diagnosis, Staging, Surgical Treatment, Non-Surgical Treatment all ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacokinetics of Antifungal Agents in Neonates and Young Infants
Current Medicinal Chemistry Incidence of Profound Hypogammaglobulinemia and Infection Rate in Lymphoma Patients Following the Combination of Chemotherapy and Rituximab
Recent Patents on Anti-Cancer Drug Discovery Targeted Hydrolysis of Beta-Amyloid with Engineered Antibody Fragments
Current Alzheimer Research A UBI 31-38 Peptide-coumarin Conjugate: Photophysical Features, Imaging Tracking and Synergism with Amphotericin B Against Cryptococcus
Current Topics in Medicinal Chemistry Disrupting β-Amyloid Aggregation for Alzheimer Disease Treatment
Current Topics in Medicinal Chemistry Drug Target in Eosinophilic Meningitis Caused by Angiostrongylus cantonensis
Infectious Disorders - Drug Targets Challenges in Chagas Disease Drug Discovery: A Review
Current Medicinal Chemistry Clinical Signs, Prevention and Treatment of Viral Infections in Infants
Infectious Disorders - Drug Targets Uveitis in Rheumatic Diseases
Current Rheumatology Reviews Tachykinins and Neuropsychiatric Disorders
Current Drug Targets Abeta DNA Vaccination for Alzheimers Disease: Focus on Disease Prevention
CNS & Neurological Disorders - Drug Targets Amyloid-β Immunotherapy for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets The Effects of Soluble Aβ Oligomers on Neurodegeneration in Alzheimer's Disease
Current Pharmaceutical Design Amyloid-Targeted Metal Chelation, Anti-Oxidative Stress, and Anti- Inflammation as Potential Alzheimers Therapies
Current Bioactive Compounds West Nile Virus Vaccine.
Current Drug Targets - Infectious Disorders Emerging Promise of Immunotherapy for Alzheimer’s Disease: A New Hope for the Development of Alzheimer’s Vaccine
Current Topics in Medicinal Chemistry DNA Microarrays - An Armory for Combating Infectious Diseases in the New Century
Infectious Disorders - Drug Targets Trypanosomatid Parasites Causing Neglected Diseases
Current Medicinal Chemistry Super aggregated form of Amphotericin B: a novel way to increase its therapeutic index
Current Pharmaceutical Design Alternative Aβ Immunotherapy Approaches for Alzheimers Disease
CNS & Neurological Disorders - Drug Targets